Search | OpenScholar

Search results

193 results found

Enteric dysbiosis and fecal calprotectin expression in premature infants.

Publication: Journal Article

Ho, Thao T B, Maureen W Groër, Bradley Kane, Alyson L Yee, Benjamin A Torres, Jack A Gilbert, and Akhil Maheshwari. 2019. “Enteric Dysbiosis and Fecal Calprotectin Expression in Premature Infants.”. Pediatric Research 85 (3): 361-68.

Red blood cell transfusions increase fecal calprotectin levels in premature infants.

Publication: Journal Article

Ho, T T B, M W Groer, A A Luciano, A Schwartz, M Ji, B S Miladinovic, A Maheshwari, and T L Ashmeade. 2015. “Red Blood Cell Transfusions Increase Fecal Calprotectin Levels in Premature Infants.”. Journal of Perinatology : Official Journal of the California Perinatal Association 35 (10): 837-41.

Leigh-Anne Worthington

Person:

USF Tina Ho Lab

The Ho lab is a laboratory in USF Health that focuses on understanding gut health in preterm infants with an emphasis on anemia and oral iron supplementation.

Halade Lab

Istradefylline - a first generation adenosine A2A antagonist for the treatment of Parkinson's disease. Expert Rev Neurother 2021;21:317-333.

Publication: Journal Article

Jenner, P, A Mori, SD Aradi, and RA Hauser. 2021. “Istradefylline - a First Generation Adenosine A2A antagonist for the Treatment of Parkinson’s Disease. Expert Rev Neurother 2021;21:317-333.”. Expert Rev Neurother.

Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol 2019;18:145-154.

Publication: Journal Article

LeWitt, PA, RA Hauser, R Pahwa, SH Isaacson, HH Fernandez, M Lew, M Saint-Hilaire, et al. 2019. “Safety and Efficacy of CVT-301 (levodopa Inhalation Powder) on Motor Function During off Periods in Patients With Parkinson’s Disease: A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial. Lancet Neurol 2019;18:145-154.”. Lancet Neurol.

Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease. Parkinsonism Relat Disord 2019;64:175-180.

Publication: Journal Article

Hauser, RA, SH Isaacson, A Ellenbogen, BE Safirstein, DD Truong, SF Komjathy, DM Kegler-Ebo, P Zhao, and C Oh. 2019. “Orally Inhaled Levodopa (CVT-301) for Early Morning OFF Periods in Parkinson’s Disease. Parkinsonism Relat Disord 2019;64:175-180.”. Parkinsonism Relat Disord.

Prevalence of Dyskinesia and OFF by 30-minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials. J Parkinsons Dis 2019;9:591-600.

Publication: Journal Article

Hauser, RA, DE Kremens, LW Elmer, DL Kreitzman, RR Walsh, R Johnson, R Howard, JT Nguyen, and R Patni. 2019. “Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials. J Parkinsons Dis 2019;9:591-600.”. J Parkinsons Dis.

Using global team science to identify genetic parkinson's disease worldwide. Ann Neurol 2019;86:153-157.

Publication: Journal Article

Vollstedt, EJ, M Kasten, C Klein, and MJFF Global Genetic Parkinson’s Disease Study Group. 2019. “Using Global Team Science to Identify Genetic Parkinson’s Disease Worldwide. Ann Neurol 2019;86:153-157.”. Ann Neurol.